FORMULATION ARTICLES
-
![Abstract Modern-GettyImages-490280002]( "Rethinking The \"3:1 Rule\" In LNP Production")
Rethinking The "3:1 Rule" In LNP ProductionA new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.
-
![Tumor microenvironment, cancer cells, t-cells, nanoparticles-GettyImages-1449007926]( "Emerging RNA Delivery Strategies For Solid Tumor Oncology")
Emerging RNA Delivery Strategies For Solid Tumor OncologyRNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.
-
![path of exponential growth-GettyImages-2229192052]( "Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing")
Trends In Oligo Scale-Up & Delivery & How They're Impacting ManufacturingHere, a panel of experts at the RNA Leaders Conference give a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.”
-
![Researcher at work in DNA genetic laboratory, virus and pathogen detection-GettyImages-1346857647]( "Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next")
Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes NextNeoVac CEO Jan Egberts, MD, discusses the science, regulation, and innovation shaping next-gen LNPs—and why true progress in mRNA therapeutics may depend more on understanding than on AI.
-
![Liposome is releasing siRNA, mRNA, or RNA-GettyImages-1656071904]( "Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA Therapeutics")
Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA TherapeuticsWhile LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more.
-
![Healthcare collaboration-GettyImages-1724755569]( "Translating An Early-Stage mRNA Therapeutic Into The Clinic")
Translating An Early-Stage mRNA Therapeutic Into The ClinicIn the following Q&A, Ethris CMO Thomas Langenickel shares some of his biggest questions and observations about the evolving mRNA therapeutics space that are the most impactful in translating early-stage RNA candidates into the clinic — particularly when that drug product boasts a novel formulation.
FORMULATION VIDEOS
CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.
In this segment, Replicate Biosciences’ Andy Geall, Qian Ruan, & Alex Aust identify the most promising technological and raw material innovations that are influencing the drug substance and drug product production processes at CDMOs.
mRNA therapeutics are applicable to cancer immunotherapies, infectious diseases, and other indications that require protein replacement therapy or antibodies.
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![mRNA GettyImages-1356994723]( "The Future Of mRNA: Four Key Focuses For Industry")
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
![iStock-1213713667-viral-vector-virus]( "Gene Therapy And Oligonucleotide Compendium")
Technical summaries and detailed protocols for purity testing, sizing, sequencing and expression analysis of oligonucleotide-based active agents as well as protein and lipid-based delivery systems.
-
![GettyImages-1182436133 scientist, lab, research, oncology]( "Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced Therapeutics")
Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced TherapeuticsPrecision in nanoparticle processing is key for drug delivery and vaccines. Learn how monodispersed formulations enhance reproducibility and stability for next-generation therapeutics, like RNA-LNPs.
-
![Crispr gene editing-GettyImages-1139760176]( "CRISPR 101 - Your Guide To Understanding CRISPR")
Review the fundamentals of CRISPR technology, development, and its use to manipulate genes in different ways, such as altering their nucleotide sequences or changing their expression.
-
![GettyImages-1392303980-chromatography-LC]( "Analysis Of LNP Lipids With Evaporative Light Scattering Detection")
Jump into this thorough analysis of lipids in LNP formulations using HPLC, a technique crucial for quality control in the production of mRNA vaccines and therapeutics.
-
![GettyImages-2174865889 lab, research]( "Tangential Flow Filtration Of LNPs Results In 10X Concentration Within 20 Minutes")
Dive into a study that details how a single-pass tangential flow filtration system can achieve a tenfold concentration of liposomal nanoparticles in under 20 minutes.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Lipid Nanoparticle Compositional Analysis By UHPLC-CAD")
Explore results generated from an internal study using a proprietary mRNA-LNP formulation and UHPLC-CAD, a powerful technique for the analysis of compounds that do not contain chromophores.
